GoodRx (GDRX) Retraction of fiscal Y2022 Guidance Case

In May 2022, GoodRx retracted its Y2022 guidance and announced negative revenue impact for Q2’22.
On it, $GDRX fell 25.9%, losing $256M+ of shareholder value.
Investors may have grounds to suspect GoodRx of having distribution problems.
On May 9, 2022, after the market closed, GoodRx announced its Q1’ 22 financial results and withdrew its fiscal 2022 guidance. 
In shareholder letter, Company indicated pricing issues with a large distributor.
Also, Company expects negative revenue impact around $30M.
It further expects the matter to be ongoing without amelioration through Q2.
On this news, $GDRX fell 25.9% and lost over $256 million of its market capitalization, seriously damaging shareholders.

Considering all the information, investors might have grounds to suspect that GoodRx and its executives failed to timely disclose and resolve distribution issues, which consequently led to their losses.

The case is already under investigation by at least one of the reputable law firms.

Case Status

Attorney Investigation

Alleged Offence

Misleading Statements,

Failure to Disclose,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

05/10/2022

GoodRx (GDRX) Retraction of fiscal Y2022 Guidance Case

Collecting participants…